Literature DB >> 23963629

Psychopharmacology for medically ill adolescents.

Brenda Bursch1, Marcy Forgey.   

Abstract

Medically ill adolescents are at increased risk for psychological distress and/or functional impairment. However, there are few research studies examining the optimal psychiatric treatments for this population. Psychiatric medication recommendations are largely based on studies of youth with a primary psychiatric disorder, adult studies, hypothesized mechanisms of action, and/or clinical experience. This paper provides evidence-informed recommendations for the psychopharmacological treatment of acutely medically ill adolescents suffering from significant psychological distress and/or functional impairment. Representing the most common problems among medically ill adolescents that are treated with psychiatric medications, recommendations are provided for anxiety and depression; iatrogenic medical trauma, inadequate sleep and insomnia; and, delirium.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23963629     DOI: 10.1007/s11920-013-0395-y

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  93 in total

Review 1.  Factors related to posttraumatic stress disorder in adolescence.

Authors:  Kate B Nooner; L Oriana Linares; Jessica Batinjane; Rachel A Kramer; Raul Silva; Marylene Cloitre
Journal:  Trauma Violence Abuse       Date:  2012-06-04

2.  Practice patterns in pediatric consultation-liaison psychiatry: a national survey.

Authors:  Richard J Shaw; Marianne Wamboldt; Brenda Bursch; Margaret Stuber
Journal:  Psychosomatics       Date:  2006 Jan-Feb       Impact factor: 2.386

3.  Pharmacotherapy of pediatric insomnia.

Authors:  Judith A Owens
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-02       Impact factor: 8.829

4.  Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study.

Authors:  C Andrade; B S Srihari; K P Reddy; L Chandramma
Journal:  J Clin Psychiatry       Date:  2001-01       Impact factor: 4.384

5.  Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder.

Authors:  Soraya Seedat; Dan J Stein; Carl Ziervogel; Tessa Middleton; Deborah Kaminer; Robin A Emsley; Wendy Rossouw
Journal:  J Child Adolesc Psychopharmacol       Date:  2002       Impact factor: 2.576

6.  The relevance of differential response to trauma in an animal model of posttraumatic stress disorder.

Authors:  Hagit Cohen; Joseph Zohar; Michael Matar
Journal:  Biol Psychiatry       Date:  2003-03-15       Impact factor: 13.382

7.  Comparison of toxicity of acute overdoses with citalopram and escitalopram.

Authors:  Bryan D Hayes; Wendy Klein-Schwartz; Richard F Clark; Allison A Muller; Jane E Miloradovich
Journal:  J Emerg Med       Date:  2008-12-11       Impact factor: 1.484

Review 8.  Multiple sclerosis in children.

Authors:  Natan Gadoth
Journal:  Brain Dev       Date:  2003-06       Impact factor: 1.961

9.  Limitations of the Glasgow Coma Scale in predicting outcome in children with traumatic brain injury.

Authors:  M W Lieh-Lai; A A Theodorou; A P Sarnaik; K L Meert; P M Moylan; A I Canady
Journal:  J Pediatr       Date:  1992-02       Impact factor: 4.406

Review 10.  New insights into secondary prevention in post-traumatic stress disorder.

Authors:  Joseph Zohar; Alzbeta Juven-Wetzler; Rachel Sonnino; Shlomit Cwikel-Hamzany; Evgenya Balaban; Hagit Cohen
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

View more
  2 in total

1.  Biopsychosocial Predictors of Quality of Life Outcomes in Pediatric Congenital Heart Disease.

Authors:  Michelle M Ernst; Bradley S Marino; Amy Cassedy; Carrie Piazza-Waggoner; Rodney C Franklin; Katherine Brown; Jo Wray
Journal:  Pediatr Cardiol       Date:  2017-10-04       Impact factor: 1.655

Review 2.  Insomnia in Adolescence.

Authors:  Innessa Donskoy; Darius Loghmanee
Journal:  Med Sci (Basel)       Date:  2018-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.